SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for the Treatment of Post Surgical Pain in the Home Setting
October 28, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent
October 21, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed to Participate in Upcoming Investor Conferences
September 02, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed Provides Insights on Recent Corporate Developments and Reports Second Quarter 2015 Financial Results
August 13, 2015 16:05 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed to Provide Insights on Recent Corporate Developments and Report Second Quarter 2015 Financial Results
August 06, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed Completes Program of Human Factors Studies Validating Usability of Trevyent
July 07, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed and Cardiome Enter Into a License Agreement for the Commercialization Rights to Trevyent(R) Outside the U.S.
June 29, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif. and VANCOUVER, Canada, June 29, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan...
SteadyMed Adds Significant Commercial Expertise to Its Board of Directors With the Appointment of Elizabeth A. Cermak
June 18, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed to Present at the JMP Securities Life Sciences Conference
June 16, 2015 11:40 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
CORRECTING and REPLACING - SteadyMed Reports Recent Developments, Financial Highlights and First Quarter 2015 Financial Results
May 14, 2015 08:53 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by SteadyMed Ltd. (Nasdaq:STDY), please note that in the first paragraph under the First...